25 XP   0   0   10

Stoke Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Stoke Therapeutics Inc together

PenkeI guess you are interested in Stoke Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Stoke Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Stoke Therapeutics Inc

I send you an email if I find something interesting about Stoke Therapeutics Inc.

Quick analysis of Stoke Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Stoke Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.47
Expected worth in 1 year
$2.92
How sure are you?
23.8%

+ What do you gain per year?

Total Gains per Share
$-0.55
Return On Investment
-4.7%

For what price can you sell your share?

Current Price per Share
$11.69
Expected price per share
$5.6 - $16.48
How sure are you?
50%

1. Valuation of Stoke Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$11.69

Intrinsic Value Per Share

$-20.19 - $-23.73

Total Value Per Share

$-16.71 - $-20.26

2. Growth of Stoke Therapeutics Inc (5 min.)




Is Stoke Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$159.5m$213.3m-$29.1m-15.8%

How much money is Stoke Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$25.1m-$23.4m-$1.6m-6.7%
Net Profit Margin-205.9%-758.8%--

How much money comes from the company's main activities?

3. Financial Health of Stoke Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#288 / 1010

Most Revenue
#435 / 1010

Most Profit
#749 / 1010

Most Efficient
#630 / 1010

What can you expect buying and holding a share of Stoke Therapeutics Inc? (5 min.)

Welcome investor! Stoke Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Stoke Therapeutics Inc.

What can you expect buying and holding a share of Stoke Therapeutics Inc?

First you should know what it really means to hold a share of Stoke Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Stoke Therapeutics Inc is $11.69. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Stoke Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Stoke Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.47. Based on the TTM, the Book Value Change Per Share is $-0.14 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Stoke Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.59-5.0%-0.54-4.6%-0.55-4.7%-0.40-3.4%-0.39-3.3%
Usd Book Value Change Per Share-0.29-2.5%-0.14-1.2%-0.18-1.5%0.060.5%0.171.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.29-2.5%-0.14-1.2%-0.18-1.5%0.060.5%0.171.4%
Usd Price Per Share5.26-7.04-14.08-21.38-20.36-
Price to Earnings Ratio-2.24--3.32--6.43--16.63--15.84-
Price-to-Total Gains Ratio-17.98--8.99--11.60--52.46--52.46-
Price to Book Ratio1.51-1.73-2.98-4.26-4.06-
Price-to-Total Gains Ratio-17.98--8.99--11.60--52.46--52.46-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.69
Number of shares85
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.140.06
Usd Total Gains Per Share-0.140.06
Gains per Quarter (85 shares)-11.705.04
Gains per Year (85 shares)-46.8020.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-47-5702010
20-94-10404030
30-140-15106150
40-187-19808170
50-234-245010190
60-281-2920121110
70-328-3390141130
80-374-3860161150
90-421-4330182170
100-468-4800202190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%5.016.00.023.8%5.016.00.023.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%5.016.00.023.8%5.016.00.023.8%

Fundamentals of Stoke Therapeutics Inc

About Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 19:18:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Stoke Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Stoke Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -962.1% means that $-9.62 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Stoke Therapeutics Inc:

  • The MRQ is -962.1%. The company is making a huge loss. -2
  • The TTM is -205.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-962.1%TTM-205.9%-756.2%
TTM-205.9%YOY-758.8%+552.9%
TTM-205.9%5Y-192.9%-13.0%
5Y-192.9%10Y-183.8%-9.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-962.1%-207.2%-754.9%
TTM-205.9%-216.8%+10.9%
YOY-758.8%-282.3%-476.5%
5Y-192.9%-436.8%+243.9%
10Y-183.8%-597.3%+413.5%
1.1.2. Return on Assets

Shows how efficient Stoke Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • -11.8% Return on Assets means that Stoke Therapeutics Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Stoke Therapeutics Inc:

  • The MRQ is -11.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.8%TTM-10.1%-1.7%
TTM-10.1%YOY-8.2%-1.9%
TTM-10.1%5Y-7.3%-2.8%
5Y-7.3%10Y-7.2%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.8%-13.3%+1.5%
TTM-10.1%-12.8%+2.7%
YOY-8.2%-11.6%+3.4%
5Y-7.3%-13.8%+6.5%
10Y-7.2%-15.6%+8.4%
1.1.3. Return on Equity

Shows how efficient Stoke Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • -16.9% Return on Equity means Stoke Therapeutics Inc generated $-0.17 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Stoke Therapeutics Inc:

  • The MRQ is -16.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.9%TTM-13.9%-3.0%
TTM-13.9%YOY-11.1%-2.9%
TTM-13.9%5Y-8.8%-5.1%
5Y-8.8%10Y-8.6%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.9%-16.9%+0.0%
TTM-13.9%-16.1%+2.2%
YOY-11.1%-14.9%+3.8%
5Y-8.8%-19.3%+10.5%
10Y-8.6%-20.1%+11.5%

1.2. Operating Efficiency of Stoke Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Stoke Therapeutics Inc is operating .

  • Measures how much profit Stoke Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,055.9% means the company generated $-10.56  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Stoke Therapeutics Inc:

  • The MRQ is -1,055.9%. The company is operating very inefficient. -2
  • The TTM is -232.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,055.9%TTM-232.5%-823.4%
TTM-232.5%YOY-850.4%+617.9%
TTM-232.5%5Y-216.6%-15.9%
5Y-216.6%10Y-206.3%-10.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,055.9%-298.0%-757.9%
TTM-232.5%-238.5%+6.0%
YOY-850.4%-288.4%-562.0%
5Y-216.6%-486.2%+269.6%
10Y-206.3%-628.4%+422.1%
1.2.2. Operating Ratio

Measures how efficient Stoke Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 11.56 means that the operating costs are $11.56 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Stoke Therapeutics Inc:

  • The MRQ is 11.559. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.573. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.559TTM3.573+7.986
TTM3.573YOY9.666-6.093
TTM3.5735Y2.648+0.925
5Y2.64810Y2.522+0.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.5593.235+8.324
TTM3.5733.310+0.263
YOY9.6663.838+5.828
5Y2.6485.679-3.031
10Y2.5227.823-5.301

1.3. Liquidity of Stoke Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Stoke Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.99 means the company has $6.99 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Stoke Therapeutics Inc:

  • The MRQ is 6.987. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.991. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.987TTM8.991-2.003
TTM8.991YOY10.193-1.202
TTM8.9915Y25.076-16.086
5Y25.07610Y25.931-0.855
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.9873.863+3.124
TTM8.9914.169+4.822
YOY10.1935.337+4.856
5Y25.0766.122+18.954
10Y25.9316.434+19.497
1.3.2. Quick Ratio

Measures if Stoke Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.86 means the company can pay off $6.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Stoke Therapeutics Inc:

  • The MRQ is 6.860. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.711. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.860TTM9.711-2.852
TTM9.711YOY16.006-6.295
TTM9.7115Y27.033-17.322
5Y27.03310Y27.784-0.751
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8603.504+3.356
TTM9.7113.991+5.720
YOY16.0065.371+10.635
5Y27.0336.088+20.945
10Y27.7846.395+21.389

1.4. Solvency of Stoke Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Stoke Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Stoke Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.30 means that Stoke Therapeutics Inc assets are financed with 30.1% credit (debt) and the remaining percentage (100% - 30.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Stoke Therapeutics Inc:

  • The MRQ is 0.301. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.270. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.301TTM0.270+0.031
TTM0.270YOY0.260+0.010
TTM0.2705Y0.128+0.142
5Y0.12810Y0.123+0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3010.339-0.038
TTM0.2700.337-0.067
YOY0.2600.271-0.011
5Y0.1280.368-0.240
10Y0.1230.388-0.265
1.4.2. Debt to Equity Ratio

Measures if Stoke Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 43.1% means that company has $0.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Stoke Therapeutics Inc:

  • The MRQ is 0.431. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.372. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.431TTM0.372+0.059
TTM0.372YOY0.351+0.020
TTM0.3725Y0.168+0.204
5Y0.16810Y0.161+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4310.392+0.039
TTM0.3720.403-0.031
YOY0.3510.335+0.016
5Y0.1680.427-0.259
10Y0.1610.461-0.300

2. Market Valuation of Stoke Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Stoke Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Stoke Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.24 means the investor is paying $-2.24 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Stoke Therapeutics Inc:

  • The EOD is -4.978. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.240. Based on the earnings, the company is expensive. -2
  • The TTM is -3.324. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.978MRQ-2.240-2.738
MRQ-2.240TTM-3.324+1.084
TTM-3.324YOY-6.432+3.108
TTM-3.3245Y-16.635+13.311
5Y-16.63510Y-15.843-0.792
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.978-2.300-2.678
MRQ-2.240-2.656+0.416
TTM-3.324-2.718-0.606
YOY-6.432-4.145-2.287
5Y-16.635-6.258-10.377
10Y-15.843-6.315-9.528
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Stoke Therapeutics Inc:

  • The EOD is -6.428. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.892. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.822. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.428MRQ-2.892-3.535
MRQ-2.892TTM-3.822+0.930
TTM-3.822YOY-2.623-1.199
TTM-3.8225Y-18.342+14.519
5Y-18.34210Y-17.468-0.873
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.428-2.974-3.454
MRQ-2.892-3.306+0.414
TTM-3.822-3.508-0.314
YOY-2.623-5.613+2.990
5Y-18.342-8.378-9.964
10Y-17.468-8.873-8.595
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Stoke Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.51 means the investor is paying $1.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Stoke Therapeutics Inc:

  • The EOD is 3.364. Based on the equity, the company is fair priced.
  • The MRQ is 1.514. Based on the equity, the company is underpriced. +1
  • The TTM is 1.729. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD3.364MRQ1.514+1.850
MRQ1.514TTM1.729-0.215
TTM1.729YOY2.978-1.250
TTM1.7295Y4.259-2.531
5Y4.25910Y4.056+0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.3641.914+1.450
MRQ1.5142.116-0.602
TTM1.7292.097-0.368
YOY2.9782.881+0.097
5Y4.2593.550+0.709
10Y4.0563.936+0.120
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Stoke Therapeutics Inc.

3.1. Institutions holding Stoke Therapeutics Inc

Institutions are holding 98.015% of the shares of Stoke Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Skorpios Trust32.345999.80221444368100
2023-12-31RTW INVESTMENTS, LLC9.25130.33944131045-259513-5.9107
2023-09-30Redmile Group, LLC8.67270.7263872696-82492-2.0857
2023-12-31COWEN AND COMPANY, LLC8.33451.284372165900
2023-12-31Morgan Stanley - Brokerage Accounts7.54780.0016337036245657815.6696
2023-12-31Goldman Sachs Group Inc6.23210.0013278286226535572052.1689
2023-12-31BlackRock Inc4.61380.00032060232-146278-6.6294
2023-12-31Baker Bros Advisors LP4.54640.1215203013454421936.6252
2023-12-31Vanguard Group Inc3.69170.00021648502178141.0924
2023-12-31Granahan Investment Management Inc..2.54820.1977113788728668633.6802
2023-12-31Cormorant Asset Management, LLC2.43610.2733108780700
2023-12-31Geode Capital Management, LLC1.37890.0003615724246074.1628
2023-12-31State Street Corporation1.21720.0001543533-42475-7.2482
2023-12-31Deutsche Bank AG0.92440.00114127783990162899.4042
2023-12-31Northern Trust Corp0.57690.0003257592-7781-2.9321
2023-12-31HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND0.53590.004223930000
2023-09-30Jacobs Levy Equity Management, Inc.0.48730.00512176052176050
2023-12-31Dimensional Fund Advisors, Inc.0.48210.0003215294-43128-16.689
2023-12-31Birchview Capital, LP0.47030.866210000125000147.0588
2023-12-31Charles Schwab Investment Management Inc0.45960.0003205242-12097-5.566
Total 96.7531103.625243203935+4131318+9.6%

3.2. Funds holding Stoke Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.22320.0005102944000
2024-03-28iShares Russell 2000 ETF1.46510.0146784073270.0482
2023-12-31HBM Healthcare Investments AG Ord1.07090.130649585400
2023-12-31M&G (ACS) Granahan US Sm Cp Gr GBPZ1AAcc0.86520.48354006253992911.07
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.83060.002938460438491.0109
2024-01-31Fidelity Small Cap Index0.60510.005528018234641.2518
2024-03-28iShares Russell 2000 Value ETF0.56840.028326318185953.3761
2023-12-31Granahan Inv Mgt Sm-Cap Core Gr0.47050.47992178377054847.8977
2023-12-31Victory Small Cap Stock0.47050.11412178377054847.8977
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.35270.00316330419001.1772
2024-02-29Fidelity Extended Market Index0.33360.0031154465-748-0.4819
2024-03-29Schwab US Small-Cap ETF™0.27210.0112597600
2024-02-29Vanguard Russell 2000 ETF0.21390.0089902978328.588
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.19080.01228834000
2023-12-31NT R2000 Value Index Fund - NL0.16310.010575536-1220-1.5895
2023-12-31NT R2000 Index Fund - NL0.1620.005475001-1111-1.4597
2023-09-30BlackRock Extended Mkt Composite0.14820.0019686434830.7086
2024-02-29Vanguard Health Care ETF0.14640.0025678043520.5219
2024-02-29Schwab Small Cap Index0.13620.00836306000
2023-06-30FIAM Small Company CIT Cl B0.13440.18076224300
Total 10.82291.50495011368+204748+4.1%

3.3. Insider Transactions

Insiders are holding 5.191% of the shares of Stoke Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-28Jonathan AllanSELL512613.2
2024-03-19Edward M Md KayeSELL111506.1
2024-03-19Jonathan AllanSELL23496.1
2024-03-19Stephen J TulipanoSELL41166.1
2024-02-01Barry TichoSELL100004.8
2024-01-02Barry TichoSELL100005.74
2023-07-03Barry TichoSELL1500010.6
2023-06-21Jonathan AllanSELL194813.48
2023-06-01Barry TichoSELL1500011.13
2023-05-03Barry TichoSELL2469710.14
2023-05-01Barry TichoSELL2496710

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Stoke Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.293-0.138-53%-0.179-39%0.059-593%0.165-277%
Book Value Per Share--3.4754.010-13%4.646-25%4.648-25%4.535-23%
Current Ratio--6.9878.991-22%10.193-31%25.076-72%25.931-73%
Debt To Asset Ratio--0.3010.270+11%0.260+16%0.128+135%0.123+145%
Debt To Equity Ratio--0.4310.372+16%0.351+23%0.168+157%0.161+168%
Dividend Per Share----0%-0%-0%-0%
Eps---0.587-0.537-9%-0.550-6%-0.403-31%-0.388-34%
Free Cash Flow Per Share---0.455-0.450-1%-0.195-57%-0.286-37%-0.276-39%
Free Cash Flow To Equity Per Share---0.295-0.162-45%0.058-612%0.105-382%0.189-256%
Gross Profit Margin--1.0221.005+2%1.000+2%1.001+2%1.001+2%
Intrinsic Value_10Y_max---23.731--------
Intrinsic Value_10Y_min---20.190--------
Intrinsic Value_1Y_max---1.505--------
Intrinsic Value_1Y_min---1.478--------
Intrinsic Value_3Y_max---5.187--------
Intrinsic Value_3Y_min---4.939--------
Intrinsic Value_5Y_max---9.671--------
Intrinsic Value_5Y_min---8.920--------
Market Cap536783758.000+55%241529732.000323264128.000-25%646643051.500-63%981616320.500-75%934872686.190-74%
Net Profit Margin---9.621-2.059-79%-7.588-21%-1.929-80%-1.838-81%
Operating Margin---10.559-2.325-78%-8.504-19%-2.166-79%-2.063-80%
Operating Ratio--11.5593.573+223%9.666+20%2.648+337%2.522+358%
Pb Ratio3.364+55%1.5141.729-12%2.978-49%4.259-64%4.056-63%
Pe Ratio-4.978-122%-2.240-3.324+48%-6.432+187%-16.635+643%-15.843+607%
Price Per Share11.690+55%5.2607.040-25%14.083-63%21.378-75%20.360-74%
Price To Free Cash Flow Ratio-6.428-122%-2.892-3.822+32%-2.623-9%-18.342+534%-17.468+504%
Price To Total Gains Ratio-39.957-122%-17.979-8.989-50%-11.598-35%-52.457+192%-52.457+192%
Quick Ratio--6.8609.711-29%16.006-57%27.033-75%27.784-75%
Return On Assets---0.118-0.101-14%-0.082-31%-0.073-38%-0.072-39%
Return On Equity---0.169-0.139-17%-0.111-35%-0.088-48%-0.086-49%
Total Gains Per Share---0.293-0.138-53%-0.179-39%0.059-593%0.165-277%
Usd Book Value--159565000.000184145250.000-13%213322500.000-25%213413900.000-25%208254571.429-23%
Usd Book Value Change Per Share---0.293-0.138-53%-0.179-39%0.059-593%0.165-277%
Usd Book Value Per Share--3.4754.010-13%4.646-25%4.648-25%4.535-23%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.587-0.537-9%-0.550-6%-0.403-31%-0.388-34%
Usd Free Cash Flow---20878000.000-20670750.000-1%-8957000.000-57%-13128950.000-37%-12675571.429-39%
Usd Free Cash Flow Per Share---0.455-0.450-1%-0.195-57%-0.286-37%-0.276-39%
Usd Free Cash Flow To Equity Per Share---0.295-0.162-45%0.058-612%0.105-382%0.189-256%
Usd Market Cap536783758.000+55%241529732.000323264128.000-25%646643051.500-63%981616320.500-75%934872686.190-74%
Usd Price Per Share11.690+55%5.2607.040-25%14.083-63%21.378-75%20.360-74%
Usd Profit---26958000.000-25112750.000-7%-23436250.000-13%-18228450.000-32%-17564333.333-35%
Usd Revenue--2802000.0002195250.000+28%3101250.000-10%1059300.000+165%1008857.143+178%
Usd Total Gains Per Share---0.293-0.138-53%-0.179-39%0.059-593%0.165-277%
 EOD+5 -3MRQTTM+4 -30YOY+4 -305Y+5 -2910Y+5 -29

4.2. Fundamental Score

Let's check the fundamental score of Stoke Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.978
Price to Book Ratio (EOD)Between0-13.364
Net Profit Margin (MRQ)Greater than0-9.621
Operating Margin (MRQ)Greater than0-10.559
Quick Ratio (MRQ)Greater than16.860
Current Ratio (MRQ)Greater than16.987
Debt to Asset Ratio (MRQ)Less than10.301
Debt to Equity Ratio (MRQ)Less than10.431
Return on Equity (MRQ)Greater than0.15-0.169
Return on Assets (MRQ)Greater than0.05-0.118
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Stoke Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose11.410
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets228,342
Total Liabilities68,777
Total Stockholder Equity159,565
 As reported
Total Liabilities 68,777
Total Stockholder Equity+ 159,565
Total Assets = 228,342

Assets

Total Assets228,342
Total Current Assets215,339
Long-term Assets13,003
Total Current Assets
Cash And Cash Equivalents 191,442
Short-term Investments 9,952
Net Receivables 64
Other Current Assets 13,881
Total Current Assets  (as reported)215,339
Total Current Assets  (calculated)215,339
+/-0
Long-term Assets
Property Plant Equipment 12,434
Long-term Assets Other 569
Long-term Assets  (as reported)13,003
Long-term Assets  (calculated)13,003
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities30,819
Long-term Liabilities37,958
Total Stockholder Equity159,565
Total Current Liabilities
Short-term Debt 2,062
Accounts payable 1,695
Other Current Liabilities 11,753
Total Current Liabilities  (as reported)30,819
Total Current Liabilities  (calculated)15,510
+/- 15,309
Long-term Liabilities
Capital Lease Obligations 2,062
Long-term Liabilities Other 4,884
Long-term Liabilities  (as reported)37,958
Long-term Liabilities  (calculated)6,946
+/- 31,012
Total Stockholder Equity
Common Stock5
Retained Earnings -401,849
Accumulated Other Comprehensive Income -24
Other Stockholders Equity 561,433
Total Stockholder Equity (as reported)159,565
Total Stockholder Equity (calculated)159,565
+/-0
Other
Capital Stock5
Cash and Short Term Investments 201,394
Common Stock Shares Outstanding 44,959
Current Deferred Revenue15,309
Liabilities and Stockholders Equity 228,342
Net Debt -184,607
Net Invested Capital 159,565
Net Working Capital 184,520
Property Plant and Equipment Gross 19,105
Short Long Term Debt Total 6,835



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-31
> Total Assets 
0
0
0
107,539
102,934
246,372
238,827
228,750
220,841
210,214
199,935
297,925
278,908
264,450
253,771
238,865
315,938
301,427
277,626
256,067
281,796
256,919
239,889
228,342
228,342239,889256,919281,796256,067277,626301,427315,938238,865253,771264,450278,908297,925199,935210,214220,841228,750238,827246,372102,934107,539000
   > Total Current Assets 
0
0
0
106,143
101,276
244,445
236,680
226,033
215,774
205,544
195,456
293,930
275,295
260,233
244,933
229,218
305,771
289,159
264,601
244,070
270,236
246,232
230,019
215,339
215,339230,019246,232270,236244,070264,601289,159305,771229,218244,933260,233275,295293,930195,456205,544215,774226,033236,680244,445101,276106,143000
       Cash And Cash Equivalents 
0
0
0
105,399
98,651
242,680
233,049
222,471
211,288
201,930
191,461
287,308
267,514
169,070
149,038
144,895
84,111
67,754
113,396
113,556
190,339
192,060
189,977
191,442
191,442189,977192,060190,339113,556113,39667,75484,111144,895149,038169,070267,514287,308191,461201,930211,288222,471233,049242,68098,651105,399000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
82,156
87,118
74,915
209,105
207,876
138,259
116,039
63,334
39,387
24,741
9,952
9,95224,74139,38763,334116,039138,259207,876209,10574,91587,11882,1560000000000000
       Net Receivables 
0
0
0
196
196
260
376
281
144
9
2
6
6
131
45
132
265
350
395
588
492
136
96
64
6496136492588395350265132451316629144281376260196196000
       Other Current Assets 
0
0
0
548
2,429
1,505
3,255
3,281
4,342
3,605
3,993
6,616
7,775
8,876
8,732
9,408
12,290
13,179
12,551
2,955
5,880
3,699
4,269
13,881
13,8814,2693,6995,8802,95512,55113,17912,2909,4088,7328,8767,7756,6163,9933,6054,3423,2813,2551,5052,429548000
   > Long-term Assets 
0
0
0
1,396
1,658
1,927
2,147
2,717
5,067
4,670
4,479
3,995
3,613
4,217
8,838
9,647
10,167
12,268
13,025
11,997
11,560
10,687
9,870
13,003
13,0039,87010,68711,56011,99713,02512,26810,1679,6478,8384,2173,6133,9954,4794,6705,0672,7172,1471,9271,6581,396000
       Property Plant Equipment 
0
0
0
1,192
1,396
1,722
1,942
2,512
4,862
4,465
4,274
3,790
3,555
4,142
8,269
9,078
9,598
11,699
12,456
11,428
10,991
10,118
9,301
12,434
12,4349,30110,11810,99111,42812,45611,6999,5989,0788,2694,1423,5553,7904,2744,4654,8622,5121,9421,7221,3961,192000
       Other Assets 
0
0
0
0
262
205
205
205
205
205
205
1,320
58
75
569
569
569
569
569
569
0
0
569
0
05690056956956956956956975581,3202052052052052052052620000
> Total Liabilities 
0
0
0
2,471
3,353
4,836
5,144
4,322
6,499
6,814
7,400
11,847
6,443
9,381
16,258
21,088
75,961
77,106
73,483
71,218
67,974
66,724
66,890
68,777
68,77766,89066,72467,97471,21873,48377,10675,96121,08816,2589,3816,44311,8477,4006,8146,4994,3225,1444,8363,3532,471000
   > Total Current Liabilities 
0
0
0
2,467
3,343
4,818
4,916
4,101
5,455
5,805
6,735
11,425
6,110
8,197
11,884
17,139
22,905
27,649
28,795
31,394
31,527
21,837
25,201
30,819
30,81925,20121,83731,52731,39428,79527,64922,90517,13911,8848,1976,11011,4256,7355,8055,4554,1014,9164,8183,3432,467000
       Short-term Debt 
0
0
0
0
0
0
0
0
1,065
1,092
1,119
0
0
592
1,425
1,507
1,535
2,080
2,313
2,359
2,404
2,450
2,498
2,062
2,0622,4982,4502,4042,3592,3132,0801,5351,5071,425592001,1191,0921,06500000000
       Accounts payable 
0
0
0
1,071
1,126
1,238
1,789
751
1,779
904
1,095
1,495
1,496
963
655
2,385
3,328
3,602
1,911
766
4,299
1,556
3,076
1,695
1,6953,0761,5564,2997661,9113,6023,3282,3856559631,4961,4951,0959041,7797511,7891,2381,1261,071000
       Other Current Liabilities 
0
0
0
1,396
2,217
3,580
3,127
3,350
54
495
255
9,930
4,614
586
328
540
9,573
11,333
11,733
13,389
11,373
9,772
10,892
11,753
11,75310,8929,77211,37313,38911,73311,3339,5735403285864,6149,930255495543,3503,1273,5802,2171,396000
   > Long-term Liabilities 
0
0
0
4
10
18
228
221
1,044
1,009
665
422
333
1,184
4,374
3,949
53,056
49,457
44,688
39,824
36,447
44,887
41,689
37,958
37,95841,68944,88736,44739,82444,68849,45753,0563,9494,3741,1843334226651,0091,04422122818104000
       Other Liabilities 
0
0
0
0
10
18
228
221
176
425
369
342
313
1,184
4,374
3,949
49,921
45,210
44,688
37,107
34,353
43,425
40,870
0
040,87043,42534,35337,10744,68845,21049,9213,9494,3741,18431334236942517622122818100000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
49,545
45,210
41,078
36,856
34,144
0
0
0
00034,14436,85641,07845,21049,5450000000000000000
> Total Stockholder Equity
-1,297
0
0
105,068
99,581
241,536
233,683
224,428
214,342
203,400
192,535
286,078
272,465
255,069
237,513
217,777
239,977
224,321
204,143
184,849
213,822
190,195
172,999
159,565
159,565172,999190,195213,822184,849204,143224,321239,977217,777237,513255,069272,465286,078192,535203,400214,342224,428233,683241,53699,581105,06800-1,297
   Common Stock
0
0
0
0
1
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
5
544444444444433333310000
   Retained Earnings Total Equity000-319,695-297,150-271,495-245,384-220,732-196,083-171,635-149,038-127,071-110,27800000000000
   Accumulated Other Comprehensive Income -24-147-379-598-1,175-1,703-1,276-684-168-22-420000-815-815000-379000
   Capital Surplus 
0
0
0
0
131,031
280,804
281,555
282,460
283,413
0
0
396,352
399,532
404,145
409,166
414,024
461,389
470,977
477,337
483,170
534,111
0
0
0
000534,111483,170477,337470,977461,389414,024409,166404,145399,532396,35200283,413282,460281,555280,804131,0310000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
0
0
131,155
131,031
280,804
281,555
283,275
283,413
285,430
288,249
396,352
399,532
404,145
409,166
414,028
461,389
470,977
477,337
483,170
534,111
540,919
548,033
561,433
561,433548,033540,919534,111483,170477,337470,977461,389414,028409,166404,145399,532396,352288,249285,430283,413283,275281,555280,804131,031131,155000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue8,780
Cost of Revenue-4,729
Gross Profit4,0514,051
 
Operating Income (+$)
Gross Profit4,051
Operating Expense-118,824
Operating Income-114,773-114,773
 
Operating Expense (+$)
Research Development79,762
Selling General Administrative41,322
Selling And Marketing Expenses2,260
Operating Expense118,824123,344
 
Net Interest Income (+$)
Interest Income0
Interest Expense-9,908
Other Finance Cost-18,708
Net Interest Income8,800
 
Pretax Income (+$)
Operating Income-114,773
Net Interest Income8,800
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-104,699-124,847
EBIT - interestExpense = -124,681
-104,699
-94,791
Interest Expense9,908
Earnings Before Interest and Taxes (EBIT)-114,773-94,791
Earnings Before Interest and Taxes (EBITDA)-110,044
 
After tax Income (+$)
Income Before Tax-104,699
Tax Provision-0
Net Income From Continuing Ops-103,396-104,699
Net Income-104,699
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses123,553
Total Other Income/Expenses Net10,074-8,800
 

Technical Analysis of Stoke Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Stoke Therapeutics Inc. The general trend of Stoke Therapeutics Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Stoke Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Stoke Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 13.82 < 16.40 < 16.48.

The bearish price targets are: 8.58 > 8.44 > 5.6.

Tweet this
Stoke Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Stoke Therapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Stoke Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartStoke Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Stoke Therapeutics Inc. The current adx is .

Stoke Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Relative Strength Index (RSI) ChartStoke Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Stochastic Oscillator ChartStoke Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Commodity Channel Index (CCI) ChartStoke Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartStoke Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Williams %R ChartStoke Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Average True Range (ATR) ChartStoke Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily On-Balance Volume (OBV) ChartStoke Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Stoke Therapeutics Inc.

Stoke Therapeutics Inc Daily Money Flow Index (MFI) ChartStoke Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Stoke Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Stoke Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Stoke Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose11.410
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Stoke Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Stoke Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Stoke Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Stoke Therapeutics Inc

I send you an email if I find something interesting about Stoke Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Stoke Therapeutics Inc.

Receive notifications about Stoke Therapeutics Inc in your mailbox!